DFTX · Definium Therapeutics, Inc.
$45.08
+2.28 (+5.33%)
At close · Jul 21
Market Cap
$4.92B
Shares
109.07M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert Barrow | CEO | $12,767,442 |
| Brandi L. Roberts | CFO | $5,116,362 |
| Daniel Karlin | Chief Medical Officer | $4,001,258 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Barrow | CEO | $2,669,010 |
| Daniel Karlin | Chief Medical Officer | $1,330,319 |
| Mark Sullivan | CFO | $1,161,107 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark Sullivan | CFO | $1,080,394 |
| Daniel Karlin | Chief Medical Officer | $1,037,272 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| JR Rahn | CEO | $14,991,351 |
| Robert Barrow | CEO | $11,889,466 |
| Daniel Karlin | Chief Medical Officer | $4,905,942 |
| Miri Halperin Wernli | Executive President | $2,663,528 |
| Stephen Hurst | CEO | $1,059,315 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| JR Rahn | CEO | $1,234,493 |
| Miri Halperin Wernli | Executive President | $996,147 |
Key facts
CIK
1813814
CUSIP
24477V105
13F (30d)
25 filings
25 filers
Visit website
Investor relations